Revenue Breakdown
Composition ()
No data
Revenue Streams
Teva Pharmaceutical Industries Ltd (TEVA) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Generic products, accounting for 57.5% of total sales, equivalent to $2.58B. Other significant revenue streams include AUSTEDO and Anda. Understanding this composition is critical for investors evaluating how TEVA navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, Teva Pharmaceutical Industries Ltd maintains a gross margin of 57.40%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 12.25%, while the net margin is 10.19%. These profitability ratios, combined with a Return on Equity (ROE) of 21.23%, provide a clear picture of how effectively TEVA converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, TEVA competes directly with industry leaders such as BNOX. With a market capitalization of $36.76B, it holds a leading position in the sector. When comparing efficiency, TEVA's gross margin of 57.40% stands against BNOX's N/A. Such benchmarking helps identify whether Teva Pharmaceutical Industries Ltd is trading at a premium or discount relative to its financial performance.
